Product Launchgenerative chemistrydrug discoveryabsciwet lab in the loop
Absci Releases Origin-1 Model, Advances AI-Designed Drugs
8.1
Absci Corporation CEO Sean McClain announced the release of Origin-1 and reported AI-designed molecules advancing toward clinical testing at the 44th JPMorgan Healthcare Conference on January 14, 2026. He said two Phase II readouts are expected within 24 months for androgenic alopecia and endometriosis, highlighting the company's six-week wet-lab-in-the-loop cycle for rapid validation and model iteration.
Key Points
- 1Announces Origin-1 model and AI-designed molecules entering clinical Phase II readouts within 24 months
- 2Emphasizes wet-lab-in-the-loop and six-week cycle for rapid model validation and iterative improvement
- 3Enables practitioners to prioritize targets and accelerate candidate selection with faster experimental feedback
Scoring Rationale
High relevance and official CEO disclosure with anticipated Phase II readouts; limited detail in brief conference excerpt.
Sources
Public references used for this report.
Practice interview problems based on real data
1,625 SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems